Bausch+Lomb Results Presentation Deck
YTD Total Bausch + Lomb P&L¹ (Non-GAAP)²
Bausch + Lomb
Vision Care Revenue4
Surgical Revenue
Pharmaceuticals Revenue 4
Total Revenue
Adj. Gross Profit²
Adj. Gross Margin²
Adj. R&D²
Adj. R&D % of Revenues
Adj. SG&A²
Adj. SG&A % of Revenues³
Adj. EBITA²
Depreciation
Stock Based Compensation
Adj. EBITDA 2,3
Adj. EBITDA
Adj. Net Income Attributable to B+L²
Adj. EPS Attributable to B+L2,4
BAUSCH+ LOMB
1Q23-3Q23
$1,881 M
$563M
$529M
$2,973 M
$1,794M
60.3%
$243M
8.2%
$1,185M
39.9%
$366M
$106M
$58M
$507M
17.1%
$175M
$0.50
1Q22-3Q225
$1,745M
$530M
$497M
$2,772M
$1,673M
60.4%
$229M
8.3%
$1,060M
38.2%
$383M
$98M
$45M
$539M
19.4%
$295M
$0.84
1. Products with sales outside the United States impacted by F/X changes.
2. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.
Reported Change
8%
6%
6%
7%
7%
(10 bps)
(6%)
(12%)
(4%)
8%
29%
(6%)
(41%)
Constant Currency Change²
11%
7%
8%
9%
10%
(6%)
(13%)
1%
7%
29%
(2%)
(34%)
3. Includes transactional FX and NCI. FX headwinds (translational and transactional) were -$52M to Adj. EBITDA for YTD2023. The YTD2022 transactional FX impact was a gain of $15M.
4. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of
the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of
these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.
5. YTD 2022 results were not fully burdened by all stand-up costs associated with the separation.
27View entire presentation